Objective: To evaluate the clinical and demographic findings of children with urolithiasis in eastern Turkey. Methods: We retrospectively reviewed the medical records of 67 children with urolithiasis for clinical and laboratory data. Results: Mean age at the time of diagnosis was 39.1 ± 41.2 months. Complaints at admission were: urinary tract infection (29.9%), macroscopic hematuria (26.9%), abdominal or flank pain (19.4%), spontaneous passing of the stone (8.9%), growth and developmental delay (7.5%), and non-specific findings (8.9%). A family history of urolithiasis was positive in 50.7% of patients. Metabolic screening could be performed in 47 (70.1%) of patients due to socioeconomic problems and revealed hypercalciuria in 59.6%, infectious stone in 17%, cystinuria in 6.4%, hyperuricosuria in 10.6%, hyperoxaluria 4.3%, and hypocitruria in 2.1%. Stone analysis of patients (26.9%) revealed calcium oxalate in 38.9%, calcium phosphate in 22.2%, uric acid in 16.7%, cystine in 11.2%, struvite in 5.6% and mixed content in 5.6%. Conclusion: We believe early diagnosis with detailed metabolic screening and appropriate treatment and follow-up procedures and the contribution of urolithiasis to end-stage renal disease can be avoided.

Keywords:
Nephrolithiasis, Pediatric urolithiasis, Urolithiasis
This content is only available via PDF.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.